Novel treatments for cardiovascular disease prevention

Mark D. Huffman*, Deepak Bhatnagar

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations

Abstract

The purpose of this review is to describe novel pharmacologic and nonpharmacologic preventive therapies, as well as new strategies to improve delivery of available therapies. Cardiovascular disease (CVD) is the leading cause of death worldwide, and prevention plays a critical role in curbing the global epidemic. Despite available treatment for tobacco addiction, platelet inhibition, blood pressure, and lipid lowering for reduction of atherosclerotic disease, significant gaps in treatment of total CVD remain. We review a range of new preventive treatment options, including drugs for tobacco cessation, platelet/thrombotic inhibition, lipid- and blood pressure-lowering; nonpharmacologic options such as left atrial appendage closure devices and caloric restriction; and strategies such as fixed-dose combination drugs, laboratory screening for drug tailoring, and community-based prevention programs. CVD preventive research continues to evolve and provide clinicians and patients with novel pharmacologic and nonpharmacologic therapies, including new preventive strategies.

Original languageEnglish (US)
Pages (from-to)257-263
Number of pages7
JournalCardiovascular Therapeutics
Volume30
Issue number5
DOIs
StatePublished - Oct 2012

Funding

Keywords

  • Cardiovascular disease
  • Novel
  • Prevention
  • Treatment

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)
  • Pharmacology

Fingerprint

Dive into the research topics of 'Novel treatments for cardiovascular disease prevention'. Together they form a unique fingerprint.

Cite this